Eagle Pharmaceuticals (EGRX) Reports Q4 EPS of $0.85, Offers Guidance

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of $0.85, versus $0.96 reported last year. Revenue for the quarter came in at $42.3 million, versus $49.9 million reported last year.

GUIDANCE:

Eagle Pharmaceuticals sees Q1 2022 EPS of $3.80-$4.10. Eagle Pharmaceuticals sees Q1 2022 revenue of $120-130 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance
• EquipmentShare raises 2026 outlook, approves $500M buyback
• Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook